Results 231 to 240 of about 212,526 (280)

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor. [PDF]

JAAD Case Rep
Kucharik AH, Curkovic NB, Chavez JC, Tsai KY, Brohl AS, Grichnik JM.   +5 more
europepmc   +1 more source

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

, 2017
Xiaojing Wang, J A Barbosa, Peter Blomgren, Meire Bremer, Jacob Chen, James J. Crawford, Wei Deng, Liming Dong, Charles Eigenbrot, Steve Gallion, Jonathon Hau, Huiyong Hu, Adam R. Johnson, Arna Katewa, Jeffrey E. Kropf, Seung‐Hwan Lee, Lichuan Liu, Joseph W. Lubach, Jen Macaluso, Pat Maciejewski, Scott A. Mitchell, Daniel F. Ortwine, Julie DiPaolo, Karin Reif, Heleen Scheerens, Aaron C. Schmitt, Harvey Wong, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao, Fusheng Zhou, Kevin Currie, Wendy B. Young   +32 more
openalex   +1 more source

Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. [PDF]

J Neuroinflammation
Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C, DeGeer J, Sudharshan TJJ, Yong VW, Shen YA, Harp C, Collin L, Keaney J.   +12 more
europepmc   +1 more source

The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas. [PDF]

Int J Mol Sci
Mehra S, Nicholls M, Taylor J.
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases. [PDF]

Cell Discov
Zhu C, Yang Z, Zhang Y, Li Z, Li G, Yang B, Kang N, Wang J, Sun Y, Ding N, Rao Y, Liu W.   +11 more
europepmc   +1 more source

Retraction: X-linked immunodeficient mice with no functional Bruton's tyrosine kinase are protected from sepsis-induced multiple organ failure. [PDF]

Front Immunol
Frontiers Editorial Office.
europepmc   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source